The Ahmedabad-based pharmaceutical company Marck Biosciences Ltd is all set to foray into the Far East countries like Malaysia, Singapore and Indonesian markets by the end of June 2008. The company is planning to offer 12 new products in the existing therapeutic segment in these markets.
The company has wide therapeutic products in the domestic as well as international market. Its large volume parenterals segment offers a complete range of common solutions, electrolyte replacements, anti-biotic solutions, diuretics anti-infective and anti-fungal solutions. Whereas, its small volume parentearls range provides diluents, ophthalmic and respiratory solutions.
In a telephonic interaction with Pharmabiz, Bhavesh Patel, managing director, Marck Biosciences Ltd, said, "We have filed 12 new dossiers in Malaysia, Singapore and Indonesia and are expected to get approvals from the respective regulatory authorities by the end of June 2008. All our 12 new products will be for the ophthalmic and injection therapeutic segment".
Recently, the company has entered the Latin American market, after receiving ANVISA approval for sterile injectibles exports to Brazil. The company will soon begin its Latin American foray with Brazil. Argentina, Chile, Columbia, Mexico, Peru and Venezuela are the other Latin American markets the company is planning to enter. It is targeting to grow 35-40 per cent in the current financial year in the international market and is expecting to achieve the total turnover of Rs 100 crore in the domestic market. With the current export turnover of Rs 12 crore, it is targeting to touch Rs 30 crore in the next financial year.
Few months back, the company had invested Rs 72 crore for expanding additional capacity of Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP). After the completion of domestic expansion, the company has its presence all over the country. Earlier, the company was having its presence in the northern and western region of India only.
Talking about future initiative in the international market, Patel, said, "We are intending to file 100 more dossiers in the existing therapeutic segment at South East Asia, Latin America and Africa by the end of current calendar year. We are also filing our product dossiers in the regulated markets like Australia, Europe and US by the end of 2008".